-+ 0.00%
-+ 0.00%
-+ 0.00%

AbbVie Receives FDA's Approval For JUVMO To Treat Adults with Parkinson's Disease

Benzinga·09/28/2026 12:02:13
Listen to the news

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease, a progressive neurological disorder that affects millions of people worldwide.